RRR schreef op 27 februari 2014 11:41:
Het wachten is hierop...
clinicaltrials.gov/ct2/show/NCT013599...echter... de primary outcome heeft safety issues...
Primary Outcome Measures:
The primary objective is the assessment of safety and tolerability (adverse events, physical examination, vital signs, immunological and routine laboratory analyses et cetera) [ Time Frame: 90 Days ] [ Designated as safety issue: Yes ]
Immunogenicity by assessing antibodies against recombinant human C1INH (IgG and IgM) anti-rhC1INH) [ Time Frame: 90 Days ] [ Designated as safety issue: Yes ]
Immunogenicity by assessing antibodies against host related impurities (anti-HRI) [ Time Frame: 90 Days ] [ Designated as safety issue: Yes ]
Immunogenicity by assessing IgE antibodies against rabbit epithelium [ Time Frame: 28 Days ] [ Designated as safety issue: Yes ]
...vandaar uitstel FDA?